Buy LLY by Sep 4, 2026.

Retatrutide has shown amazing promises early on then with the grey market its been showing amazing results and now that they are coming out with trial 3 results and it looks even more promising they are ready to ignite that rocket fuel. They hit it out of the park with Tirzepatide, Novo has no real good answer their latest clinical results for their pipeline Zenagamtide hasn't shown much promise to get past Tirzepatide and far beind Reatrutide. Get ready for …